{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:45:15Z","timestamp":1740141915670,"version":"3.37.3"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jpurol.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jpurol.2024.04.019","type":"journal-article","created":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:05:24Z","timestamp":1714867524000},"page":"600.e1-600.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Results of a study examining the use of onabotulinumtoxinA in pediatric patients with overactive bladder"],"prefix":"10.1016","volume":"20","author":[{"given":"Piet","family":"Hoebeke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5470-5768","authenticated-orcid":false,"given":"Adam","family":"Hittelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Geib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson","family":"Titanji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5989-1253","authenticated-orcid":false,"given":"Guy","family":"Bogaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpurol.2024.04.019_bib1","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.5489\/cuaj.4337","article-title":"Overactive bladder in children","volume":"11","author":"Ramsay","year":"2017","journal-title":"Can Urol Assoc Journal"},{"key":"10.1016\/j.jpurol.2024.04.019_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/nau.22751","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society","volume":"35","author":"Austin","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2024.04.019_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00148581-200709060-00005","article-title":"Pediatric overactive bladder syndrome: pathophysiology and management","volume":"9","author":"Franco","year":"2007","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jpurol.2024.04.019_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1442-2042.2006.01217.x","article-title":"Nocturnal enuresis and overactive bladder in children: an epidemiological study","volume":"13","author":"Kajiwara","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.urology.2008.06.063","article-title":"Prevalence and associated factors of overactive bladder in Korean children 5-13 years old: a nationwide multicenter study","volume":"73","author":"Chung","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.jpurol.2024.04.019_bib6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00431-020-03681-w","article-title":"EAU-ESPU guidelines recommendations for daytime lower urinary tract conditions in children","volume":"179","author":"Tekgul","year":"2020","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jpurol.2024.04.019_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-5347(05)00416-7","article-title":"Childhood urinary symptoms predict adult overactive bladder symptoms","volume":"175","author":"Fitzgerald","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/01.AOG.0000190222.12436.38","article-title":"Effect of childhood dysfunctional voiding on urinary incontinence in adult women","volume":"107","author":"Minassian","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib9","first-page":"167","article-title":"Clinical utility of \u03b2(3)-adrenoreceptor agonists for the treatment of overactive bladder: a review of the evidence and current recommendations","volume":"14","author":"Krhut","year":"2022","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4111\/icu.20200380","article-title":"Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: a preliminary study","volume":"62","author":"Kim","year":"2021","journal-title":"Invest Clin Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2016.02.007","article-title":"Prospective pilot study of mirabegron in pediatric patients with overactive bladder","volume":"70","author":"Blais","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib12","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/01.ju.0000152322.17542.63","article-title":"Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials","volume":"173","author":"Nijman","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib13","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.juro.2017.05.038","article-title":"Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder","volume":"198","author":"Newgreen","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpurol.2022.07.012","article-title":"Urodynamic evaluation of the efficacy of vibegron, a new \u03b23-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder","volume":"18","author":"Kitta","year":"2022","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib15","doi-asserted-by":"crossref","first-page":"351.e1","DOI":"10.1016\/j.jpurol.2022.02.007","article-title":"Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder","volume":"18","author":"Lambregts","year":"2022","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0022-5347(06)00301-6","article-title":"The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor","volume":"176","author":"Hoebeke","year":"2006","journal-title":"J Urol"},{"year":"2021","series-title":"Botox [package insert]. Madison, NJ: allergan","key":"10.1016\/j.jpurol.2024.04.019_bib17"},{"key":"10.1016\/j.jpurol.2024.04.019_bib18","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.juro.2017.01.069","article-title":"The efficacy and safety of onabotulinumtoxinA or solifenacin compared with placebo in solifenacin na\u00efve patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial","volume":"198","author":"Herschorn","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/SPV.0000000000000914","article-title":"Early and consistent improvements in urinary symptoms and quality of life with onabotulinumtoxinA in patients with overactive bladder and urinary incontinence: results from a randomized, placebo-controlled, phase IV clinical trial","volume":"27","author":"McCammon","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.jpurol.2024.04.019_bib22","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib23","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1002\/sim.1300","article-title":"Combined endpoints: can we use them?","volume":"21","author":"Lubsen","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jpurol.2024.04.019_bib24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1159\/000020351","article-title":"Lower urinary tract dysfunction and urodynamics in children","volume":"38","author":"Hjalmas","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2024.04.019_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: a systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2019","journal-title":"J Adv Nurs"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513124002560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513124002560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T15:12:40Z","timestamp":1728141160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477513124002560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1477513124002560"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2024.04.019","relation":{},"ISSN":["1477-5131"],"issn-type":[{"type":"print","value":"1477-5131"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a study examining the use of onabotulinumtoxinA in pediatric patients with overactive bladder","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2024.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AbbVie Inc. Published by Elsevier Ltd on behalf of Journal of Pediatric Urology Company.","name":"copyright","label":"Copyright"}]}}